COVID-19 testing at ultra-high-throughput

Enabling mass testing with scalable technology, capable of processing up to 150,000 tests per day on a single system.
The need for population-scale testing

Current COVID-19 diagnostic strategies are not sufficient to manage the spread of the virus. Population-scale COVID-19 testing, combined with contact tracing and isolation, offers hope in slowing and containing the spread of the virus.

Supply limitations and process constraints mean that many asymptomatic and pre-symptomatic people are not able to get tested. In order to support mass testing, it is necessary to overcome the capacity restrictions of current testing strategies, which range between 4,000 to 8,000 tests per day for PCR machines used today.

Large scale and repeat testing will allow universities, businesses and other organizations to remain open and keep economies moving. LGC, Biosearch Technologies has created fast, streamlined and continuous lab workflow processes for COVID-19 testing. These processes are able to process up to 150,000 samples per day on a single system.

Contact us to discuss our ultra-high-throughput platform

The scientific community continues to call for large scale and frequent testing as a key response to help manage the spread of COVID-19. It will allow us to assess positivity rates in communities, measure trends and identify hot spots where additional action is required. Click below to view our mass testing infographic.

View our mass testing infographic
The Biosearch Technologies SARS-CoV-2 testing systems from LGC

A scalable technology for COVID-19 testing based on our proven PCR instrumentation and reagents. This system is capable of enabling testing volumes ranging from 4,500 tests per day, up to 150,000 tests per day, on a single platform. Click below to view our workflow infographic.

Evaluate options for scaling up COVID-19 testing
Explore our RT-PCR system, submitted for EUA

View platform details
Resources to support scaling up

LGC enables rapid, large-scale implementation of laboratory diagnostics for COVID-19 by expediting availability of mission-critical extraction chemistries, oligos, PCR reagents, quality control solutions, and instrumentation that deliver 2019 Novel Coronavirus detection kits at scale.

Visit our COVID-19 Resources Hub

Uniquely positioned to support mass testing

LGC’s market-leading expertise and components in clinical research testing, coupled with its strong partner relationships, has enabled the company to respond quickly to the COVID-19 pandemic since January 2020, and we are committed to being part of the worldwide solution for managing the spread of COVID-19. The use of LGC’s technology will allow for large-scale screening to help unlock the potential in bringing some sense of “normalcy” back into our daily activities.

LGC is proud to have worked with customers including many of the world leading IVD companies, clinical laboratories, governments and regulatory agencies to quickly respond to this pandemic.

Working with you to wield science for a safer world.